Category Archives: brigatinib-Alunbrig from Takeda

Upcoming ASCO abstracts

There are 14 abstracts for the upcoming ASCO that have ALK in the title. But only 6 look like they are likely to be broadly applicable to people on this board. I will be posting summaries over the next week … Continue reading

Posted in alectinib - Alecensa from Chugai - Roche - GenenTech, Brain metastases, brigatinib-Alunbrig from Takeda, crizotinib - Xalkori from Pfizer, lorlatinib - Lorbrena by Pfizer, Lung cancer | Leave a comment

Additional Brigatinib info

Ariad has posted a new presentation from European Lung Cancer Conference on their website for a limited time. Pages 7-13 are most relevant. Page 8 shows a breakdown of how patients ¬†responded by dose. 90 mg had a ORR of … Continue reading

Posted in Brain metastases, brigatinib-Alunbrig from Takeda, Lung cancer, Potential Treatments, Research, Side Effects | Leave a comment

Ariad announces start of Phase 3 trial

Ariad today announced the initiation of a first line phase 3 trial comparing Brigatinib with Crizotinib. Patients must be ALK inhibitor naive. They are planning to enroll around 270 patients. They expect to complete enrollment in 2018. Of interest, the … Continue reading

Posted in brigatinib-Alunbrig from Takeda, Lung cancer, Potential Treatments, Research | Leave a comment

Brigatinib update

Thanks to Dave for pointing this out. This info can be found on Ariad’s site under Investors, presentations. It’s from the Cowan Healthcare presentation which may only be available for a few weeks. The relevant info is on pages 15-16. … Continue reading

Posted in brigatinib-Alunbrig from Takeda, Lung cancer, Potential Treatments, Research | Leave a comment

Article on latest develpments

In January 2016 an article was published that reviewed the current status of nine 2nd generation and 3rd generation ALK inhibitors, some HSP 90 inhibitors and briefly 2 immunotherapies for lung cancer. Much of that research has been described in … Continue reading

Posted in alectinib - Alecensa from Chugai - Roche - GenenTech, ASP3026 from Astellas, brigatinib-Alunbrig from Takeda, CEP-37440, ceritinib - Zykadia from Novartis, Imunotherapies, lorlatinib - Lorbrena by Pfizer, Lung cancer, NMS-E628, Potential Treatments, Research, Resistance to treatment, RXDX-101 - entrectinib - by Ignyta, Side Effects, TSR-011 from Tesaro, X-396 - ensartinib from Xcovrery | Leave a comment

Editorial on Brain mets and ALK lung cancer

The Journal of Clinical Oncology has an editorial about the current research on treating brain mets for ALK+ patients that discusses ALK inhibitors and different kinds of radiation treatments. Treatments discussed include: 1) Crizotinib, 2) Ceritinib 3) Alectinib 4) brigatinib, … Continue reading

Posted in alectinib - Alecensa from Chugai - Roche - GenenTech, Brain metastases, brigatinib-Alunbrig from Takeda, ceritinib - Zykadia from Novartis, crizotinib - Xalkori from Pfizer, Lung cancer, Potential Treatments, Research, Resistance to treatment, Side Effects | Leave a comment

Survey of ALK inhibitors effects on brain mets

This survey summarizes the results of other research to describe the current level of knowledge about how effective different ALK inhibitors are at treating brain mets. Inhibitors that are discussed include crizotinib, ceritinib, alectinib, AP26113 (brigatinib) and PF-06463922 (lorlatinib). http://www.thecco.net/article/view/6520/7543

Posted in alectinib - Alecensa from Chugai - Roche - GenenTech, Brain metastases, brigatinib-Alunbrig from Takeda, ceritinib - Zykadia from Novartis, crizotinib - Xalkori from Pfizer, lorlatinib - Lorbrena by Pfizer, Lung cancer, Potential Treatments, Research | Leave a comment

Ariad’s Brigatinib trial

Ariad has fully enrolled the Phase 2 trial for Brigatinib. It is likly that it is much harder to get into the trial now. I have not heard of them giving ethical exemptions yet. http://investor.ariad.com/mobile.view?c=118422&v=203&d=1&id=2087810

Posted in Brain metastases, brigatinib-Alunbrig from Takeda, Lung cancer, Potential Treatments, Research | Leave a comment

Ariad plans to file NDA in 3rd quarter of 2016

Ariad plans to file a new drug application (NDA) for brigatnib in 3rd quarter of 2016. http://investor.ariad.com/mobile.view?c=118422&v=203&d=1&id=2075920

Posted in Brain metastases, brigatinib-Alunbrig from Takeda, Lung cancer, Potential Treatments, Regulatory applications & approvals | Leave a comment

Comparison of 3 ALK inhibitors’ phase 2 trials

All of these results are based on 5 phase 2 trials. However the conditions of each trial may differ in important ways. For example, it is my understanding that the trial for brigatinib was limited to healthier patients while the … Continue reading

Posted in alectinib - Alecensa from Chugai - Roche - GenenTech, Brain metastases, brigatinib-Alunbrig from Takeda, ceritinib - Zykadia from Novartis, Lung cancer, Potential Treatments, Research, Resistance to treatment | Leave a comment